Tananbaum James B.
SEC-identified person · CIK 1581754 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Alumis INC. NASDAQ | Director | filed 2024 - 2026 |
| Kinnate Biopharma Inc. KNTE | Director | filed 2020 - 2024 |
| Pardes Biosciences, INC. PRDS | Director · President and CEO | filed 2021 - 2023 |
| Theseus Pharmaceuticals, Inc. THRX | Officer | filed 2022 - 2023 |
| Aclaris Therapeutics, Inc. ACRS | Officer | filed 2021 - 2021 |
| Gemini Therapeutics, Inc. /DE IRON | Director · President and CEO | filed 2020 - 2021 |
| Quantum-Si Inc QSI | Director | filed 2021 - 2021 |
| 10x Genomics, Inc. TXG | Officer | filed 2019 - 2020 |
| Aerie Pharmaceuticals INC AERI | Officer | filed 2016 - 2020 |
| Aimmune Therapeutics, Inc. AIMT | Officer | filed 2015 - 2016 |
| Intellia Therapeutics, Inc. NTLA | Officer | filed 2016 - 2016 |
| Ambit Biosciences Corp AMBI | Officer | filed 2013 - 2013 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.